Thiamine-responsive megaloblastic anaemia syndrome
Zuletzt aktualisiert 9. Dez 2024
Erfüllt die redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Ask Patient
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
Thiamine-responsive megaloblastic anaemia syndrome (TRMA) is a rare condition that is characterised by hearing loss, diabetes, and a blood disorder called megaloblastic anaemia. Megaloblastic anaemia occurs when a person has a low number of red blood cells (anaemia), and the red blood cells that are present are larger than normal (megaloblastic). The symptoms of this blood disorder may include decreased appetite, lack of energy, headaches, pale skin, diarrhea, and tingling or numbness in the hands and feet. Individuals with TRMA typically develop megaloblastic anaemia between infancy and adolescence. TRMA is called "thiamine-responsive" because the anaemia can be treated with daily doses of vitamin B1 (thiamine).
Videoauswahl für Genetische ErkrankungenVideothek
Beschreibung
Thiamine-responsive megaloblastic anaemia syndrome (TRMA) is a rare condition that is characterised by hearing loss, diabetes, and a blood disorder called megaloblastic anaemia. Megaloblastic anaemia occurs when a person has a low number of red blood cells (anaemia), and the red blood cells that are present are larger than normal (megaloblastic). The symptoms of this blood disorder may include decreased appetite, lack of energy, headaches, pale skin, diarrhea, and tingling or numbness in the hands and feet. Individuals with TRMA typically develop megaloblastic anaemia between infancy and adolescence. TRMA is called "thiamine-responsive" because the anaemia can be treated with daily doses of vitamin B1 (thiamine).
In people with TRMA, hearing loss typically develops during early childhood and is caused by abnormalities of the inner ear (sensorineural hearing loss). The hearing loss usually worsens over time. It remains unclear whether treatment with thiamine can improve hearing or delay hearing loss in people with TRMA.
People with TRMA often develop diabetes mellitus, a condition in which glucose levels can become dangerously high, at an early age. Although some individuals with TRMA develop diabetes during childhood, they do not have the autoimmune form of diabetes that typically develops in children, called type 1 diabetes. People with TRMA usually require insulin to treat their diabetes. In some cases, treatment with thiamine may delay the onset of diabetes or reduce the amount of insulin a person needs.
Some individuals with TRMA have abnormalities of the eye, including optic atrophy, which is the degeneration (atrophy) of the nerves that carry information from the eyes to the brain. Additional features of this condition may include heart and blood vessel (cardiovascular) problems, intellectual disabilities, behavioural changes, and seizures.
Inheritance patterns
The source lists the following possible inheritance patterns: Autosomal recessive. More than one pattern can apply in different cases.
Related genes
Other names
Rogers syndrome
Thiamine-responsive megaloblastic anaemia with diabetes mellitus and sensorineural hearing loss
TRMA
Related patient information and medicines

Patient information leaflet
Makrozytose und makrozytäre Anämie
Macrocytosis refers to red blood cells which are larger than normal. There are two types of macrocytic anaemia: Megaloblastic macrocytic anaemia Non-megaloblastic macrocytic anaemia The difference is in the presence or absence of megaloblasts. These are larg... Causes of megaloblastic macrocytic anaemia include: Serum B12 deficiency (when.

Patient information leaflet
Refeeding-Syndrom
Refeeding syndrome was first described in Far East prisoners after the second world wa... Refeeding syndrome is a dangerous and life threatening shift of fluids and body salts (electrolytes) that can occur when malnourished patients receive treatment with refeeding. These shifts cause serious complications such as low body phosphate, abnormal.

Patient information leaflet
Vitamin-B12-Mangel und perniziöse Anämie
If the body does not absorb enough vitamin B12 then this causes various health problems, including anaemia. This type of anaemia is called pernicious anaemia. Pernicious anaemia is classified as an autoimmune disease. The immune system normally makes antibodies to attack bacteria, viruses and other germs. If you have an autoimmune disease, the.

Patient information leaflet
Anämie
Anämie means that you have fewer red blood cells than normal or you have less haemoglobin than normal in each red blood cell. In either case, a reduced amount of oxygen is carried around in the bloodstream. Anaemia types and causes Iron-deficiency anaemia Lack of iron is the most common type of anaemia in the UK. This is called iron-deficiency.

Patient information leaflet
Nephrotisches Syndrom
Nephrotisches Syndrom is a condition where the 'filters' in the kidney become 'leaky' und large amounts of protein leak from the blood into the urine. The main symptom is fluid retention (oedema) which is mainly due to the low protein level in the blood. Various diseases can cause nephrotic syndrome, some more serious than others. The most common.

Patient information leaflet
Restless-Legs-Syndrom
Restless legs syndrome causes uncomfortable feelings in your legs. As a result, you have an urge to move your legs which gives temporary relief. Symptoms come on... Medication can ease symptoms if the condition is distressing. What is restless legs syndrome. Restless legs syndrome (RLS) is sometimes called Willis-Ekbom disease after the doctors.
Weiterführende Lektüre und Referenzen
- Thiamine-responsive megaloblastic anaemia syndrome; MedlinePlus, National Library of Medicine.
- Baron D, Assaraf YG, Cohen N, Aronheim A. Lack of plasma membrane targeting of a G172D mutant thiamine transporter derived from Rogers syndrome family. Mol Med. 2002 Aug;8(8):462-74.
- Diaz GA, Banikazemi M, Oishi K, Desnick RJ, Gelb BD. Mutations in a new gene encoding a thiamine transporter cause thiamine-responsive megaloblastic anaemia syndrome. Nat Genet. 1999 Jul;22(3):309-12. doi: 10.1038/10385.
- Habeb AM, Flanagan SE, Zulali MA, Abdullah MA, Pomahacova R, Boyadzhiev V, Colindres LE, Godoy GV, Vasanthi T, Al Saif R, Setoodeh A, Haghighi A, Haghighi A, Shaalan Y; International Neonatal Diabetes Consortium; Hattersley AT, Ellard S, De Franco E. Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome. Diabetologia. 2018 May;61(5):1027-1036. doi: 10.1007/s00125-018-4554-x. Epub 2018 Feb 15.
- Liberman MC, Tartaglini E, Fleming JC, Neufeld EJ. Deletion of SLC19A2, the high affinity thiamine transporter, causes selective inner hair cell loss and an auditory neuropathy phenotype. J Assoc Res Otolaryngol. 2006 Sep;7(3):211-7. doi: 10.1007/s10162-006-0035-x. Epub 2006 Apr 27.
- Lorber A, Gazit AZ, Khoury A, Schwartz Y, Mandel H. Cardiac manifestations in thiamine-responsive megaloblastic anemia syndrome. Pediatr Cardiol. 2003 Sep-Oct;24(5):476-81. doi: 10.1007/s00246-002-0215-3.
- Olsen BS, Hahnemann JM, Schwartz M, Ostergaard E. Thiamine-responsive megaloblastic anaemia: a cause of syndromic diabetes in childhood. Pediatr Diabetes. 2007 Aug;8(4):239-41. doi: 10.1111/j.1399-5448.2007.00251.x.
- Ricketts CJ, Minton JA, Samuel J, Ariyawansa I, Wales JK, Lo IF, Barrett TG. Thiamine-responsive megaloblastic anaemia syndrome: long-term follow-up and mutation analysis of seven families. Acta Paediatr. 2006 Jan;95(1):99-104. doi: 10.1080/08035250500323715.
- Sako S, Tsunogai T, Oishi K. Thiamine-Responsive Megaloblastic Anemia Syndrome. 2003 Oct 24 [updated 2022 Jul 28]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1282/
- Zhang S, Qiao Y, Wang Z, Zhuang J, Sun Y, Shang X, Li G. Identification of novel compound heterozygous variants in SLC19A2 and the genotype-phenotype associations in thiamine-responsive megaloblastic anemia. Clin Chim Acta. 2021 May;516:157-168. doi: 10.1016/j.cca.2021.01.025. Epub 2021 Feb 9.
Artikelverlauf
Artikel auch verfügbar in Englisch, Deutsch, Spanisch, Französisch, Italienisch, Portugiesisch, Hindi, Hebräisch, Arabisch, und Schwedisch.
9. Dez 2024 | Neueste Version
1 Dec 2024 | Ursprünglich veröffentlicht
Teilen Sie Ihre Gedanken oder Erfahrungen mit anderen in unserem Patientengemeinschaften.
Abonnieren Sie den Patienten-Newsletter
Ihre wöchentliche Dosis klarer, vertrauenswürdiger Gesundheitsberatung - geschrieben, um Ihnen zu helfen, sich informiert, selbstbewusst und in Kontrolle zu fühlen.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.

